Aetna · Identified Aug 13, 2026Medium impact
Pancreaticoduodenectomy (Whipple Resection) (CPB 0365, reviewed 2026-05-22)
Aetna considers pancreaticoduodenectomy (Whipple resection) medically necessary for ampullary adenoma or carcinoma, cholangiocarcinoma, chronic pancreatitis, combined pancreatic and duodenal injury, duodenal neoplasm, intraductal papillary mucinous neoplasm of the pancreas with high-grade dysplasia or invasive cancer, neuroendocrine tumors, and pancreatic adenocarcinoma. Aetna considers Whipple resection experimental, investigational, or unproven for Zollinger-Ellison syndrome. Immuno-nutrition, intraoperative liquid biopsy for detecting R1 resection, intraoperative pancreas stump perfusion assessment, and pre-operative biliary drainage with an omental flap for preventing complications are listed as experimental, investigational, or unproven.